The U.S. Food and Drug Administration has granted full approval to lecanemab, a treatment for early-stage Alzheimer’s disease that was shown in late-stage trials to slow cognitive decline. The decision marks a significant step for patients and families facing a condition that has long had limited treatment options.

According to the Reuters report, the monoclonal antibody was tested in phase 3 studies and was found to reduce the pace of decline by 35% compared with standard care in eligible patients. The drug is intended for people in the earlier stages of the disease, when intervention may have the most impact.

Lecanemab is part of a newer class of medicines aimed at targeting the biological processes linked to Alzheimer’s rather than only managing symptoms. While the approval offers fresh hope, the treatment is not a cure, and access, cost, and possible side effects are likely to remain important considerations.

The ruling reflects continued pressure on regulators and drugmakers to expand options for a disease that affects millions of families worldwide. For patients and caregivers, the approval may represent one of the most meaningful advances in Alzheimer’s treatment in years.